bioAffinity Technologies
NASDAQ: BIAFSan Anonio, US · Founded 2014 · Delaware corporation
Biotech
Founders & leadership
MZ
Maria ZannesChief Executive Officer
VR
Vivienne RebelChief Science and Medical Officer
XR
Xavier RevelesChief Operating Officer
TP
Timothy P. ZannesExecutive VP and Secretary
MD
Michael DoughertyChief Financial Officer
MH
Myron HolubiakDirector
BF
Barry FrankelDirector
GR
Gary RubinDirector
JP
Jamie PlattDirector
PK
Peter KnightDirector
SD
Stuart DiamondDirector
RJ
Roby JoyceDirector
Competitors · 8
by search overlapDiabetes Prevention Program29 shared keywords
智慧芽 (PatSnap)25 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Czytaj więcej22 shared keywords
by Catepillar20 shared keywords
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Cowles_Investments_StemCentrx17 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
New York, NY16 shared keywords
Altor Bioscience16 shared keywords
Companies competing with bioAffinity Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$4MofferedOct 2024 · 5 investors · BiotechnologyRule 506(b)
▶$4MofferedOct 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stuart DiamondDirector
- Vivienne RebelExecutive Officer
- Xavier RevelesExecutive Officer
- James EdwardsExecutive Officer
- Robert AndersonDirector
- Maria ZannesExecutive Officer, Director
- Steven GirgentiExecutive Officer, Director
- Roby JoyceDirector
- Jamie PlattDirector
- Peter S. KnightDirector
- Gary RubinDirector
- Timothy P. ZannesExecutive Officer
- Offering amount
- $4M
- Sales commissions
- $213K
- Placement agents
- Wallachbeth Capital LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$450KraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$450KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary RubinDirector
- Maria ZannesExecutive Officer, Director
- Roby JoyceDirector
- Robert A. AndersonDirector
- Jamie PlattDirector
- Xavier RevelesExecutive Officer
- Stuart DiamondDirector
- Michael DoughertyExecutive Officer
- Peter KnightDirector
- Timothy P. ZannesExecutive Officer
- Vivienne RebelExecutive Officer
- Steven GirgentiDirector
- Offering amount
- $450K
- Amount sold
- $450K
- Sales commissions
- $36K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$1.3MraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vivienne RebelExecutive Officer
- Gary RubinDirector
- Xavier RevelesExecutive Officer, Director
- Jamie PlattDirector
- Maria ZannesExecutive Officer, Director
- Peter KnightDirector
- Stuart DiamondDirector
- Roby JoyceDirector
- Robert A. AndersonDirector
- Steven GirgentiDirector
- Timothy P. ZannesExecutive Officer
- Michael DoughertyExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Sales commissions
- $104.2K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedMar 2024 · 3 investors · BiotechnologyRule 506(b)
▶$2.6MraisedMar 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roby JoyceDirector
- Maria ZannesExecutive Officer, Director
- Vivienne RebelExecutive Officer
- Michael DoughertyExecutive Officer
- Jamie PlattDirector
- Timothy P. ZannesExecutive Officer
- Steven GirgentiExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $2.6M
- Sales commissions
- $225K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJul 2017 · 39 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2017 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Myron HolubiakDirector
- Barry FrankelDirector
- Steven GirgentiDirector
- Maria ZannesExecutive Officer, Director
- Robert AndersonDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.